Troglitazone, a PPAR-γ agonist, decreases LTC concentration in mononuclear cells in patients with asthma.

BACKGROUND

Asthma is an inflammatory disorder with multiple mediators involved in the inflammatory response. Despite several attempts, no new anti-inflammatory drugs have been registered for asthma treatment for several years. However, thiazolidinediones, peroxisome proliferator-activated receptor agonists, have demonstrated some anti-inflammatory properties in various experimental settings. The aim of this study was to assess the influence of troglitazone on LTC and 15-HETE concentrations. It also evaluates TNF-induced eotaxin synthesis in peripheral blood mononuclear cells from 14 patients with mild asthma and 13 healthy controls.

METHODS

PBMCs were isolated from the whole blood of the asthmatics and healthy subjects and pretreated with 0.1, 1 or 10μM of Troglitazone. The cells were then exposed to 10M calcium jonophore or 10ng/ml TNF. The production and release of LTC, 15-HETE and eotaxin were then assessed.

RESULTS

Troglitazone caused a dose-dependent inhibition in LTC synthesis in both asthmatics and healthy subjects. Troglitazone did not influence 15-HETE or eotaxin production in either asthmatic patients or in healthy individuals.

CONCLUSION

Due to its inhibition of LTC synthesis, troglitazone therapy is an interesting potential therapeutic approach in asthma and other LTC related inflammatory disorders.

Copyright © 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.